NCT05264259 New Therapeutic Approach Against BK Virus Infection Based on Monoclonal Antibodies
| NCT ID | NCT05264259 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Strasbourg, France |
| Condition | BK Virus Infection |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2022-09-05 |
| Primary Completion | 2022-09-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2022-09-05 with a primary completion date of 2022-09-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
BK virus (BKV) infection has a major negative impact on transplant recipients. No BKV-specific antiviral therapy is available, so there is an urgent need to develop new anti-BKV preventive and therapeutic strategies.
Eligibility Criteria
Inclusion Criteria: * BK positive * adult * ok to participed to research Exclusion Criteria: * under guardianship * under curatorship * opposed to research * deprived of liberty
Contact & Investigator
Samira FAFI-KREMER
PRINCIPAL INVESTIGATOR
University Hospital, Strasbourg, France
Frequently Asked Questions
Who can join the NCT05264259 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying BK Virus Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05264259 currently recruiting?
Yes, NCT05264259 is actively recruiting participants. Contact the research team at anne-sophie.gey@chru-strasbourg.fr for enrollment information.
Where is the NCT05264259 trial being conducted?
This trial is being conducted at Strasbourg, France.
Who is sponsoring the NCT05264259 clinical trial?
NCT05264259 is sponsored by University Hospital, Strasbourg, France. The principal investigator is Samira FAFI-KREMER at University Hospital, Strasbourg, France. The trial plans to enroll 100 participants.